Levoketoconazole
- US DailyMed: Levoketoconazole
administration
- H02CA04 (WHO)
- US: WARNING[1]Rx-only[2]
- 1-[4-(4-{[(2S,4R)-2-(2,4-Dichlorophenyl)-2-(1H-imidazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy}phenyl)-1-piperazinyl]ethanone
- 142128-57-2
- 47576
- DB05667
- 43284
- 2DJ8R0NT7K
- D10950
- CHEBI:47518
- ChEMBL295698
- KLN (PDBe, RCSB PDB)
- DTXSID60161949
- Interactive image
- CC(=O)N1CCN(CC1)c2ccc(cc2)OC[C@@H]3CO[C@@](O3)(Cn4ccnc4)c5ccc(cc5Cl)Cl
- InChI=1S/C26H28Cl2N4O4/c1-19(33)31-10-12-32(13-11-31)21-3-5-22(6-4-21)34-15-23-16-35-26(36-23,17-30-9-8-29-18-30)24-7-2-20(27)14-25(24)28/h2-9,14,18,23H,10-13,15-17H2,1H3/t23-,26-/m1/s1
- Key:XMAYWYJOQHXEEK-ZEQKJWHPSA-N
Levoketoconazole, sold under the brand name Recorlev, is a steroidogenesis inhibitor that is used for the treatment of Cushing's syndrome.[3][4][5][6] Levoketoconazole was approved for medical use in the United States in December 2021.[7][8]
Levoketoconazole is the levorotatory or (2S,4R) enantiomer of ketoconazole,[4][5][6] and it is an inhibitor of the enzymes CYP11B1 (11β-hydroxylase), CYP17A1 (17α-hydroxylase/17,20-lyase), and CYP21A2 (21-hydroxylase).[3][4][6] It inhibits glucocorticoid biosynthesis and hence circulating levels of glucocorticoids, thereby treating Cushing's syndrome.[3][6] In addition to its increased potency, the drug is 12-fold less potent than racemic ketoconazole in inhibiting CYP7A1 (cholesterol 7α-hydroxylase), theoretically resulting in further reduced interference with bile acid production and metabolite elimination and therefore less risk of hepatotoxicity.[6] Levoketoconazole has also been found to inhibit CYP11A1 (cholesterol side-chain cleavage enzyme) and CYP51A1 (lanosterol-14α-demethylase), similarly but more potently relative to ketoconazole.[9]
References
- ^ "FDA-sourced list of all drugs with black box warnings (Use Download Full Results and View Query links.)". nctr-crs.fda.gov. FDA. Retrieved 22 October 2023.
- ^ "Recorlev- levoketoconazole tablet". DailyMed. 12 January 2022. Retrieved 20 February 2022.
- ^ a b c "Levoketoconazole - Strongbridge Biopharma". AdisInsight. Springer Nature Switzerland AG.
- ^ a b c Laws Jr ER, Pace L (11 November 2016). Cushing's Disease: An Often Misdiagnosed and Not So Rare Disorder. Elsevier Science. pp. 113–. ISBN 978-0-12-804390-5.
- ^ a b Geer EB (1 December 2016). The Hypothalamic-Pituitary-Adrenal Axis in Health and Disease: Cushing's Syndrome and Beyond. Springer. pp. 170–. ISBN 978-3-319-45950-9.
- ^ a b c d e Cuevas-Ramos D, Lim DS, Fleseriu M (2016). "Update on medical treatment for Cushing's disease". Clinical Diabetes and Endocrinology. 2 (1): 16. doi:10.1186/s40842-016-0033-9. PMC 5471955. PMID 28702250.
- ^ "Levoketoconazole: FDA-Approved Drugs". U.S. Food and Drug Administration (FDA). Retrieved 3 January 2022.
- ^ "Xeris Biopharma Announces U.S. FDA Approval of Recorlev (levoketoconazole) for the Treatment of Endogenous Hypercortisolemia in Adult Patients With Cushing's Syndrome" (Press release). Xeris Biopharma. 30 December 2021. Retrieved 3 January 2022 – via Business Wire.
- ^ Thieroff-Ekerdt R, Lavin P, Abou-Gharbia M, France N (October 2016). Pharmacology of COR-003 (levoketoconazole), an investigational treatment for endogenous Cushing's syndrome (PDF). Pituitary disorders—it’s not the anterior pituitary (posters). Endocrine Society. pp. SAT-547–SAT-547. Archived from the original (PDF) on 20 September 2020. Retrieved 30 April 2017.
External links
- "Levoketoconazole". Drug Information Portal. U.S. National Library of Medicine.
- Clinical trial number NCT03277690 for "A Study to Assess the Safety and Efficacy of Levoketoconazole in the Treatment of Endogenous Cushing's Syndrome" at ClinicalTrials.gov
- Clinical trial number NCT01838551 for "Treatment for Endogenous Cushing's Syndrome (SONICS)" at ClinicalTrials.gov
- v
- t
- e
(no additional rings)
- 2C-B-PP
- 3,4-CFP
- Acaprazine
- Antrafenine
- Aripiprazole
- Batoprazine
- Bifeprunox
- BRL-15,572
- Ciprofloxacin
- CSP-2503
- Dapiprazole
- DCPP
- DMPP
- Diphenylpiperazine
- Dropropizine
- EGIS-12,233
- Elopiprazole
- Eltoprazine
- Enpiprazole
- Ensaculin
- Etoperidone
- Flesinoxan
- Fluanisone
- Flibanserin
- Fluprazine
- Itraconazole
- Ketoconazole
- Levodropropizine
- Lorpiprazole
- mCPP
- Mefway
- MeOPP
- Mepiprazole
- Naftopidil
- Naluzotan
- Naphthylpiperazine
- Nefazodone
- Niaprazine
- Oxypertine
- Pardoprunox
- pCPP
- pFPP
- Posaconazole
- S-14,506
- S-14,671
- S-15,535
- SB-258,585
- SB-271,046
- SB-357,134
- SB-399,885
- Sonepiprazole
- TFMPP
- Tolpiprazole
- Trazodone
- Urapidil
- Vesnarinone
- Vilazodone
- Vortioxetine
- WAY-100,135
- WAY-100,635
(benzhydrylalkylpiperazines)
- AD-1211
- Almitrine
- Amperozide
- BRL-15,572
- Buclizine
- BW373U86
- Cetirizine
- Chlorbenzoxamine
- Chlorcyclizine
- Cinnarizine
- Clocinizine
- Cyclizine
- DBL-583
- Diphenpipenol
- Diphenylmethylpiperazine
- Dotarizine
- DPI-221
- DPI-287
- DPI-3290
- GBR-12,783
- GBR-12,935
- GBR-13,069
- GBR-13,098
- GBR-13,119
- Hydroxyzine
- JJC8-088
- Lidoflazine
- Manidipine
- Meclozine
- MT-45
- Oxatomide
- SNC-80
- Vanoxerine
(piperazine attached via side chain)
- Amoxapine
- Clopenthixol
- Clorotepine
- Clozapine
- Cyanothepin
- Doclothepin
- Docloxythepin
- Flupentixol
- Fluphenazine
- Isofloxythepin
- Loxapine
- Meperathiepin
- Metitepine
- Octomethothepin
- Olanzapine
- Opipramol
- Oxyclothepin
- Oxyprothepin
- Peradithiepin
- Perathiepin
- Perazine
- Perphenazine
- Pirenzepine
- Prochlorperazine
- Thiethylperazine
- Thiothixene
- Trifluoperazine
- Trifluthepin
- Zuclopenthixol